Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vevye
- Development stage
- Approved
- Lead developer
- Novaliq
- Modality
- Small Molecules, Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
Vevye is a prescription ophthalmic solution containing cyclosporine 0.1% (1 mg/mL), indicated for the treatment of the signs and symptoms of dry eye disease in adults. Cyclosporine is an immunosuppressive agent that acts as a calcineurin inhibitor, reducing ocular surface inflammation associated with dry eye disease and thereby improving tear production. Vevye utilizes EyeSol, a water-free technology designed to enhance absorption and prolong the effect of cyclosporin on the ocular surface. The most common side effects are instillation site reactions (such as irritation) and temporary blurred vision[1][3][4][5].
- Brand names
- vevye
- Other names
- cyclosporine ophthalmic solution 0.1%
02
Targets
CN (Calcineurin)
Beyond the preview
Go deeper on vevye.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vevye.